323O - Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Date 07 October 2016
Event ESMO 2016 Congress
Session CNS tumours
Topics Central Nervous System Malignancies
Presenter Enrico Franceschi
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors E. Franceschi1, D. De Biase2, A. Paccapelo1, M. Reni3, A. Mura1, G. Tallini2, C. Bortolotti4, L. Volpin5, G. Marucci6, L. Cirillo7, A. Pession2, C. Ghimenton8, R. Poggi1, S. Bartolini1, L. Albini Riccioli7, A. Tosoni1, C. Degli Esposti9, D. Danieli10, G. Genestreti1, A.A. Brandes1
  • 1Medical Oncology, Bellaria - Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, 40139 - Bologna/IT
  • 2Department Of Biomedical And Neuromotor Sciences (dibinem), Section Of Pathology, M. Malpighi, Bellaria Hospital, University of Bologna, 40139 - Bologna/IT
  • 3Medical Oncology, IRCCS San Raffaele, 20132 - Milano/IT
  • 4Neurosurgery, Irccs, Istituto Delle Scienze Neurologiche Di Bologna, Ospedale Bellaria, 40139 - Bologna/IT
  • 5Department Of Neuroscience And Neurosurgery, Ospedale San Bortolo, 36100 - Vicenza/IT
  • 6Section Of Pathology, M. Malpighi, Bellaria Hospital, 40139 - Bologna/IT
  • 7Irccs Institute Of Neurological Sciences, Unit Of Neuroradiology, Ospedale Bellaria, Bologna/IT
  • 8Pathology Department, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Trento", 37126 - Verona/IT
  • 9Radiotherapy, Bellaria - Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, 40139 - Bologna/IT
  • 10Department Of Pathology, Ospedale San Bortolo, 36100 - Vicenza/IT

Abstract

Background

Molecular characterization of low grade gliomas (LGG) has improved in recent years and is essential for diagnosis and treatment of these diseases. Moreover, clinical factors, such as age and the extent of surgery retain a prognostic role in LGG that were assessed for IDH1/2, 1p/19q codeletion, and MGMT methylation status.

Methods

we retrospectively evaluated all adult LGG patients (pts) from our data warehouse who received surgery and had sufficient tissue to assess biomarkers characterization. IDH1/2 assessment was performed on formalin-fixed paraffin-embedded samples by PCR, MGMT by methylation specific PCR, 1p/19 codeletion by FISH.

Results

198 consecutive LGG were included. The median age was 38 (range:18–72). Median follow up was 74.0 months, 109 pts (55.1%) were

Conclusions

Molecular characteristic of LGG define the prognosis of these tumors. Moreover, clinical risk assessment retains a role even in the era of molecular characterization.

Clinical trial identification

Legal entity responsible for the study

Azienda USL / IRCCS Institute of Neurological Sciences of Bologna

Funding

Azienda USL / IRCCS Institute of Neurological Sciences of Bologna

Disclosure

All authors have declared no conflicts of interest.